Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrutinib and Durvalumab combination study in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)

Next Previous
Trial Profile

Ibrutinib and Durvalumab combination study in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Ibrutinib (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 22 Dec 2018 New trial record
  • 16 Nov 2018 Results assessing safety and efficacy of combination drug ibrutinib and durvalumab in patients with follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top